Principia Biopharma, Inc.

Sanofi , in the midst of recasting itself as an immunology-focused firm, revealed a successful topline Phase III readout in immune thrombocytopenia (ITP) on 23 April for its BTK inhibitor rilzabrutini

With multiple companies looking to address treatment shortcomings in chronic spontaneous urticaria (CSU) with standard of care Xolair, Celldex Therapeutics, Inc. presented Phase II data at the Ameri

The life science venture capital firm SR One has closed its second fund since it was spun out of GSK plc in 2020, bringing in $600m to back early- and later-stage biotechs in the US and Europe that

Sanofi has hit a regulatory road bump as the US FDA placed its MS candidate tolebrutinib on clinical hold following concerns over liver toxicities, but strong enrollment numbers mean impact on studie